Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04948333
Recruitment Status : Recruiting
First Posted : July 1, 2021
Last Update Posted : June 30, 2022
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of the study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs). Patients for this study will be identified based on warning criteria and resistance definition following European Leukemia Network (ELN) 2020 recommendations.

In addition, the study will investigate the use of two different posologies. For this, patients will receive asciminib 40 mg (twice-daily) BID or of 80 mg (once daily) once daily (QD).


Condition or disease Intervention/treatment Phase
Chronic Myelogenous Leukemia Drug: ABL001 40mg BID Drug: ABL001 80mg QD Drug: ABL001 200mg QD Phase 3

Detailed Description:

This study is an international, multi-center, non-comparative, phase IIIb, treatment optimization study of daily 80 mg asciminib (as either as 40 mg BID of asciminib or as 80 mg QD) in adult patients previously treated with 2 or more TKIs. Up to 30 patients who are intolerant to ongoing TKI treatment but in major molecular response (MMR) will also be allowed to enter the trial. Enrollment will be used to have a balance in the allocation of treatment into either asciminib 40 mg b.i.d. or 80 mg q.d. Although this trial will not be powered to compare both treatments, descriptive data from both treatment groups is expected to provide additional insight into the optimal patient management In patients not achieving MMR at 48 weeks or losing the response after the week 48 up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation. In addition, there must not be any grade 3 or 4 toxicity while on therapy, or persistent grade 2 toxicity, possibly related to asciminib and unresponsive to optimal management.

The planned duration of treatment is up to 144 weeks unless patient discontinue from treatment due to unacceptable toxicity, disease progression and/or if treatment is discontinued at the discretion of the investigator or the participant prior to week 144.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 195 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3b, Multi-center, Open-label, Treatment Optimization Study of Oral Asciminib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Previously Treated With 2 or More Tyrosine Kinase Inhibitors.
Actual Study Start Date : October 13, 2021
Estimated Primary Completion Date : May 10, 2024
Estimated Study Completion Date : June 11, 2026


Arm Intervention/treatment
Experimental: ABL001
Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
Drug: ABL001 40mg BID
One tablet of 40 mg will be taken orally twice a day (BID)
Other Name: asciminib

Drug: ABL001 80mg QD
Two tablets of 40 mg will be taken orally once a day (QD)
Other Name: asciminib

Drug: ABL001 200mg QD
Five tablets of 40 mg will be taken orally once a day (QD)
Other Name: asciminib




Primary Outcome Measures :
  1. Major molecular response (MMR) rate at Week 48 for all patients with no evidence of MMR at baseline. [ Time Frame: Week 48 ]

    To estimate the molecular response rate at week 48 of all patients (40 mg BID asciminib and 80 mg QD) with CML-CP following two or more prior TKI treatments and with no evidence of MMR at baseline.

    A patient will be counted as having achieved MMR at week 48 if he/she meets the MMR criterion (BCR-ABL1 ≤ 0.1% IS) at week 48 while on study treatment and without meeting any treatment failure criteria prior to week 48.



Secondary Outcome Measures :
  1. MMR rate at baseline at Week 12, 24, 36, 72, 96 and 144 for patients with no MMR at baseline. [ Time Frame: Week 12, 24, 36, 72, 96 and 144. ]
    To assess the rate of MMR in patients without MMR at Baseline. MMR is defined as BCR-ABL ratio ≤0.1%.

  2. MMR rate at Week 48 for patients with MMR at baseline [ Time Frame: Week 48. ]
    To assess the rate of MMR for patients with MMR at Baseline. MMR is defined as BCR-ABL ratio ≤0.1%.

  3. Time to MMR. [ Time Frame: From the date of enrollment to the date of first documented MMR, assessed up to 144 weeks ]
    To assess the time to MMR. MMR is defined as BCR-ABL ratio ≤0.1%.

  4. Rate of BCR-ABL1 ≤ 10% [ Time Frame: Week 12, 24, 36 and 48. ]
    To assess the rate of early responses of BCR-ABL1 ≤10%.

  5. Rate of BCR-ABL1 ≤1% [ Time Frame: Week 12, 24, 36 and 48. ]
    To assess the rate of early responses of BCR-ABL1 ≤1%.

  6. MR4 rate. [ Time Frame: Week 12, 24, 36, 48, 72, 96 and 144. ]
    To assess the rate of deep molecular responses MR4. MR4 is defined as BCR-ABL ratio ≤0.01%.

  7. MR4.5 rate. [ Time Frame: Week 12, 24, 36, 48, 72, 96 and 144. ]
    To assess the rate of deep molecular responses MR4.5. MR4.5 is defined as BCR-ABL ratio ≤0.0032%.

  8. Rate of complete cytogenetic response (CCyR). [ Time Frame: Week 48 and end of treatment (up to 144 weeks) ]
    To assess the rate of complete cytogenetic response (CCyR). CCyR is defined as 0% Ph+ metaphases in the bone marrow.

  9. Occurrence of high-risk additional chromosomal abnormalities (ACA) [ Time Frame: Up to 144 weeks ]
    Occurrence of high-risk ACA to characterize the impact of additional cytogenetic abnormalities on efficacy.

  10. Cumulative molecular response rate of BCR-ABL1 ≤ 10%. [ Time Frame: From enrollment to end of treatment up to 144 weeks. ]
    To assess cumulative molecular responses (BCR-ABL1 ≤ 10%) by all-time points.

  11. Cumulative molecular response rate of BCR-ABL1 ≤1%. [ Time Frame: From enrollment to end of treatment up to 144 weeks. ]
    To assess cumulative molecular responses (BCR-ABL1 ≤1%) by all-time points.

  12. Cumulative molecular response rate of MMR. [ Time Frame: From enrollment to end of treatment up to 144 weeks. ]
    To assess cumulative molecular responses of MMR by all-time points. MMR is defined as BCR-ABL ratio ≤0.1%.

  13. Cumulative molecular response rate of MR4. [ Time Frame: From enrollment to end of treatment up to 144 weeks. ]
    To assess cumulative molecular responses of MR4 by all-time points. MR4 is defined as BCR-ABL ratio ≤0.01%.

  14. Cumulative molecular response rate of MR4.5. [ Time Frame: From enrollment to end of treatment up to 144 weeks. ]
    To assess cumulative molecular responses of MR4.5 by all-time points. MR4.5 is defined as BCR-ABL ratio ≤0.0032%.

  15. Duration of MMR. [ Time Frame: From the date of the first documented molecular response at MMR level to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks. ]

    Duration of MMR is defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to accelerated phase (AP) or blast crisis (BC), or CML-related death.

    MMR is defined as BCR-ABL ratio ≤0.1%.


  16. Duration of MR4 without loss of MMR. [ Time Frame: From the date of first documented MR4 without loss of MMR to the date of first documented loss of the response level or death due to any cause, whichever occurs first, assessed up to 144 weeks. ]

    Duration of MR4 is the time from the date of the first documented MR4 without loss of MMR to the date of first documented loss of the response level or death due to any cause, whichever occurs first.

    MR4 is defined as BCR-ABL ratio ≤0.01%.


  17. Progression-Free survival (PFS) [ Time Frame: Up to 144 weeks. ]
    PFS is defined as the time from treatment assignment the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause, assessed up to approximately 144 weeks.

  18. Overall Survival (OS) [ Time Frame: Up to 144 weeks. ]
    OS is defined as the time from treatment assignment to death due to any cause during study, assessed up to 144 weeks.

  19. Treatment failure (TTF) [ Time Frame: Up to 144 weeks. ]
    Time from treatment assignment to treatment failure defined as BCR-ABL1>10%, assessed up to 144 weeks.

  20. Change in symptom burden and interference from baseline over time according to the MDASI-CML PRO instrument. [ Time Frame: Week 4, 12, 24, 48, 72, 96, 120 and at end of treatment (up to 144 weeks). ]
    To evaluate patient reported outcomes and quality of life by using QoL scale. The MD Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) is a 26 item self-administered questionnaire for adult CML patients. Twenty of the items measure the severity of disease-related symptoms (symptom burden) and are scored from 0 (not present) to 10 (as bad as you can imagine) and 6 items that measure symptom interference with daily life (interference) scored from 0 (did not interfere) to 10 (interfered completely). For symptom burden, total scores range from 0 to 200 and for interference range from 0 to 60, with higher scores indicates high impact on severity of chronic myeloid leukemia-related symptoms and on impact of these symptoms on daily functioning for the patient.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

Male or female patients with a diagnosis of CML-CP ≥ 18 years of age

Patients must meet all the following laboratory values at the screening visit:

  • < 15% blasts in peripheral blood and bone marrow
  • < 30% blasts plus promyelocytes in peripheral blood and bone marrow
  • < 20% basophils in the peripheral blood
  • ≥ 50 x 109/L (≥ 50,000/mm3) platelets
  • Transient prior therapy related thrombocytopenia (< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly Prior treatment with a minimum of 2 prior TKIs (i.e. imatinib, nilotinib, dasatinib, bosutinib, radotinib or ponatinib) Warning or failure (adapted from the 2020 ELN Recommendations) or intolerance to the most recent TKI therapy at the time of screening
  • Warning is defined as:

    • Three months after the initiation of treatment: BCR-ABL1 > 10% IS
    • Six months after the initiation of treatment: BCR-ABL1 >1-10% IS
    • Twelve months after the initiation of treatment BCR-ABL1>0,1-1% IS
    • At any time after the initiation of therapy BCR-ABL1 >0.1-1% IS, loss of MMR (>0.1% with 5-fold increase of BCR-ABL1 transcripts).
  • In addition, patients with failure of treatment according to the ELN 2020 recommendations will be eligible:

    • Three months after the initiation of treatment: BCR-ABL1 > 10% IS if confirmed within 1-3 months
    • Six months after the initiation of treatment: BCR-ABL1 >10% IS
    • Twelve months after the initiation of treatment BCR-ABL1 >1% IS
    • At any time after the initiation of therapy BCR-ABL1 >1% IS, emergence of resistance mutations, high-risk ACA
  • Intolerance is defined as:

    • Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal)
    • Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute neutrophil count [ANC] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer

Exclusion criteria:

Known presence of the BCR-ABL1 T315I mutation at any time prior to study entry. Known history of AP/BC Previous treatment with a hematopoietic stem-cell transplantation Patient planning to undergo allogeneic hematopoietic stem cell transplantation

Cardiac or cardiac repolarization abnormality, including any of the following:

  • History of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
  • Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block, permanent pace maker)
  • QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients)
  • Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:

    • Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/ symptomatic bradycardia
    • Concomitant medication(s) with a "Known risk of Torsades de Pointes" (per www.crediblemeds.org/) that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication.
    • Inability to determine the QTcF interval Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension) History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis History of active ongoing acute or chronic liver disease Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 days after last dose of asciminib.

Other Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04948333


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals novartis.email@novartis.com

Locations
Layout table for location information
Austria
Novartis Investigative Site Recruiting
Graz, Austria, 8036
Novartis Investigative Site Recruiting
Linz, Austria, 4010
Novartis Investigative Site Recruiting
Wien, Austria, 1140
Canada
Novartis Investigative Site Recruiting
Quebec, Canada, G1J 1Z4
France
Novartis Investigative Site Recruiting
Bordeaux, France, 33076
Novartis Investigative Site Recruiting
Lyon Cedex, France, 69373
Novartis Investigative Site Recruiting
Montpellier cedex 5, France, 34295
Novartis Investigative Site Recruiting
Nantes Cedex 1, France, 44093
Novartis Investigative Site Recruiting
Paris Cedex 10, France, 75475
Germany
Novartis Investigative Site Recruiting
Mannheim, Baden-Wuerttemberg, Germany, 68305
Novartis Investigative Site Recruiting
Berlin, Germany, 13353
Novartis Investigative Site Recruiting
Frankfurt, Germany, 60590
Novartis Investigative Site Recruiting
Jena, Germany, 07740
Novartis Investigative Site Recruiting
Kiel, Germany, 24116
Novartis Investigative Site Recruiting
Muenchen, Germany, 80377
Greece
Novartis Investigative Site Recruiting
Thessaloniki, GR, Greece, 570 10
Novartis Investigative Site Recruiting
Athens, Greece, 115 27
Italy
Novartis Investigative Site Recruiting
Verona, VR, Italy, 37126
Korea, Republic of
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 03080
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 03722
Novartis Investigative Site Recruiting
Seoul, Korea, Republic of, 06351
Novartis Investigative Site Recruiting
Taegu, Korea, Republic of, 41944
Malaysia
Novartis Investigative Site Recruiting
Kota Kinabalu, Sabah, Malaysia, 88586
Novartis Investigative Site Recruiting
Johor Bahru, Malaysia, 80100
Novartis Investigative Site Recruiting
Penang, Malaysia, 10990
Novartis Investigative Site Recruiting
Selangor, Malaysia, 68000
Poland
Novartis Investigative Site Recruiting
Katowice, Poland, 40-519
Novartis Investigative Site Recruiting
Krakow, Poland, 31-503
Novartis Investigative Site Recruiting
Warszawa, Poland, 02 776
Russian Federation
Novartis Investigative Site Withdrawn
Moscow, Russian Federation, 127644
Singapore
Novartis Investigative Site Recruiting
Singapore, Singapore, 119074
Novartis Investigative Site Recruiting
Singapore, Singapore, 169608
Novartis Investigative Site Recruiting
Singapore, Singapore, S308433
Spain
Novartis Investigative Site Recruiting
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site Recruiting
Santiago de Compostela, Galicia, Spain, 15706
Novartis Investigative Site Recruiting
Bilbao, Pais Vasco, Spain, 48013
Novartis Investigative Site Recruiting
Madrid, Spain, 28041
Novartis Investigative Site Recruiting
Santa Cruz de Tenerife, Spain, 38009
United Kingdom
Novartis Investigative Site Recruiting
London, United Kingdom, SE1 9RT
Novartis Investigative Site Recruiting
London, United Kingdom, W12 0HS
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04948333    
Other Study ID Numbers: CABL001A2302
First Posted: July 1, 2021    Key Record Dates
Last Update Posted: June 30, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
ABL001
Phase 3
Chronic Myelogenous Leukemia
CML
tyrosine kinase inhibitor
Chronic myelogenous leukemia (CML)
chronic myeloid leukemia (CML)
chronic myelocytic leukemia (CML)
chronic granulocytic leukemia (CGL)
cancer of the white blood cells
clonal bone marrow stem cell disorder
proliferation of mature granulocytes
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Neoplasms
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Niacinamide
Vitamin B Complex
Vitamins
Micronutrients
Physiological Effects of Drugs